Skip to Content
  • Previous Rank
    173
  • Revenues ($M)
    $52,546
  • Revenue Percent Change
    -0.5%
  • Profits ($M)
    $21,308.00
  • Profits Percent Change
    195.3%
  • Assets ($M)
    $171,797.00
  • Employees
    90,200

Last year marked the end of an era for Pfizer. As the company’s patent exclusivity expired for Viagra, its blockbuster erectile dysfunction drug, the pharmaceutical giant has struggled to discover its next big hit. In January, Pfizer discontinued its research into treatments for Alzheimer’s and Parkinson’s. And after long resisting calls to split itself up, the company found itself mulling whether to sell its consumer health care business to suitors such as Procter & Gamble. Meanwhile Pfizer, which acquired biosimilars maker Hospira in 2015, is still working to address that company’s manufacturing issues, which have led to drug shortages.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
Ian C. Read
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York City
Websitehttp://www.pfizer.com
Years on Global 500 List24
Employees90,200

Pfizer Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$52,546-0.5%
Profits ($M)$21,308.00195.3%
Assets ($M)$171,797.00-
Total Stockholder Equity ($M)$71,308.00-

Profit Ratios

Profit as % of Revenues40.6%
Profits as % of Assets12.4%
Profits as % of Stockholder Equity29.9%